Skip to main content
. 2021 Jun 30;33(3):289–301. doi: 10.21147/j.issn.1000-9604.2021.03.01

Table 10. Treatment strategies for newly-diagnosed classic Hodgkin lymphoma.

Stage Stratification Category I recommendations Category II recommendations
ABVD, doxorubicin, bleomycin, vinblastine and dacarbazine; AVD, doxorubicin, vinblastine and dacarbazine; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone; ISRT, involved-site radiotherapy.
I−II Favorable ABVD × (2−4) cycles + ISRT (20 Gy)
(Level 1A evidence)
ABVD × 2 cycles + dose-escalated BEACOPP × 2 cycles + ISRT (30 Gy)
(Level 1A evidence)
Unfavorable ABVD × 4 cycles + ISRT (30 Gy)
(Level 1A evidence)
ABVD × 2 cycles + dose-escalated BEACOPP × 2 cycles + ISRT (30 Gy)
(Level 1A evidence) 		Dose-escalated BEACOPP × 2 cycles + ABVD × 2 cycles + ISRT (30 Gy)
(Level 1B evidence)
III−IV ABVD × 6 cycles ± ISRT
(Level 1A evidence)
Dose-escalated BEACOPP × (4−6) cycles ± ISRT
(Level 1A evidence)
ABVD × 2 cycles + AVD × 4 cycles ± ISRT
(Level 1A evidence) 		ABVD × 2 cycles + dose-escalated BEACOPP × 4 cycles ± ISRT
(Level 2B evidence)
Brentuximab vedotin + AVD × 6 cycles ± ISRT
(Level 1B evidence)